Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk

References

• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet19943448934138313897968073
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study GroupN Engl J Med199833919134913579841303
   PubMed Web of Science ®Google Scholar
• SacksFMThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigatorsN Engl J Med199633514100110098801446
   PubMed Web of Science ®Google Scholar
• ShepherdJPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study GroupN Engl J Med199533320130113077566020
   PubMed Web of Science ®Google Scholar
• DownsJRPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention StudyJAMA199827920161516229613910
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation2002106253143342112485966
   PubMed Web of Science ®Google Scholar
• ChapmanMJRaising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-CCurr Med Res Opin20042081253126815324528
   PubMed Web of Science ®Google Scholar
• MillerMImpact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trialJ Am Coll Cardiol200851772473018279736
   PubMed Web of Science ®Google Scholar
• ShepherdJPravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialLancet200236093461623163012457784
   PubMed Web of Science ®Google Scholar
• SeverPSPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336193641149115812686036
   PubMed Web of Science ®Google Scholar
• DavidsonMHReducing residual risk for patients on statin therapy: the potential role of combination therapyAm J Cardiol2005969A3K13Kdiscussion 34K–35K.
   PubMed Web of Science ®Google Scholar
• CollinsRMRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialLancet200336193742005201612814710
   PubMed Web of Science ®Google Scholar
• ShepherdJEffect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) studyDiabetes Care20062961220122616731999
   PubMed Web of Science ®Google Scholar
• KearneyPMEfficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysisLancet2008371960711712518191683
   PubMed Web of Science ®Google Scholar
• BaigentCEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536694931267127816214597
   PubMed Web of Science ®Google Scholar
• GarveyWTEffects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonanceDiabetes200352245346212540621
   PubMed Web of Science ®Google Scholar
• OtvosJDMeasurement issues related to lipoprotein heterogeneityAm J Cardiol2002908A22i29i
   PubMed Web of Science ®Google Scholar
• GordonDJHigh-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studiesCirculation19897918152642759
   PubMed Web of Science ®Google Scholar
• BarterPHDL cholesterol, very low levels of LDL cholesterol, and cardiovascular eventsN Engl J Med2007357131301131017898099
   PubMed Web of Science ®Google Scholar
• BerlinerJAAtherosclerosis: basic mechanisms. Oxidation, inflammation, and geneticsCirculation1995919248824967729036
   PubMed Web of Science ®Google Scholar
• GrundySMLow-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapyCirculation2002106202526252912427645
   PubMed Web of Science ®Google Scholar
• BrunzellJDLipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology FoundationJ Am Coll Cardiol200851151512152418402913
   PubMed Web of Science ®Google Scholar
• BaysHESafety considerations with omega-3 fatty acid therapyAm J Cardiol2007996A35C43C
   PubMed Web of Science ®Google Scholar
• BaysHEPrescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implicationsExpert Rev Cardiovasc Ther20086339140918327998
   PubMedGoogle Scholar
• YokoyamaMEffects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysisLancet200736995671090109817398308
   PubMed Web of Science ®Google Scholar
• DavidsonMHEfficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled studyClin Ther20072971354136717825687
   PubMed Web of Science ®Google Scholar
• HolmanRRAtorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trialDiabetologia2009521505919002433
   PubMed Web of Science ®Google Scholar
• BrownBGExpert commentary: niacin safetyAm J Cardiol2007996A32C34C
   PubMed Web of Science ®Google Scholar
• The Coronary Drug Project Research GroupClofibrate and niacin in coronary artery diseaseJAMA19752313603811088963
   PubMed Web of Science ®Google Scholar
• GansDJLetter: Coronary drug projectJAMA1975234121221174217
   PubMed Web of Science ®Google Scholar
• CannerPLFifteen year mortality in Coronary Drug Project patients: long-term benefit with niacinJ Am Coll Cardiol198686124512553782631
   PubMed Web of Science ®Google Scholar
• McKenneyJNew perspectives on the use of niacin in the treatment of lipid disordersArch Intern Med2004164769770515078639
   PubMedGoogle Scholar
• GanjiSHNiacin and cholesterol: role in cardiovascular disease (review)J Nutr Biochem200314629830512873710
   PubMed Web of Science ®Google Scholar
• Lamon-FavaSExtended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteinsArterioscler Thromb Vasc Biol20082891672167818566298
   PubMed Web of Science ®Google Scholar
• RubicTStimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacinBiochem Pharmacol200467341141915037193
   PubMed Web of Science ®Google Scholar
• BallantyneCMComparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)Am J Cardiol2008101101428143618471454
   PubMed Web of Science ®Google Scholar
• KarasRHLong-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS studyAm J Cardiovasc Drugs200882698118422390
   PubMed Web of Science ®Google Scholar
• BrownBGSimvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary diseaseN Engl J Med2001345221583159211757504
   PubMed Web of Science ®Google Scholar
• TaylorAJArterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statinsCirculation2004110233512351715537681
   PubMed Web of Science ®Google Scholar
• TaylorAJThe effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER3Curr Med Res Opin200622112243225017076985
   PubMed Web of Science ®Google Scholar
• TaylorAJHDL-C response to extended release NiacinJ Clin Lipidiol20082285288
   PubMed Web of Science ®Google Scholar
• ManninenVJoint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatmentCirculation199285137451728471
   PubMed Web of Science ®Google Scholar
• GoldenbergISecondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trialJ Am Coll Cardiol200851445946518222357
   PubMed Web of Science ®Google Scholar
• FruchartJCPeroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosisCurr Opin Lipidol199910324525710431661
   PubMed Web of Science ®Google Scholar
• BarbierOPleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosisArterioscler Thromb Vasc Biol200222571772612006382
   PubMed Web of Science ®Google Scholar
• KeechAEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialLancet200536695001849186116310551
   PubMed Web of Science ®Google Scholar
• KeechACEffect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trialLancet200737096001687169717988728
   PubMed Web of Science ®Google Scholar
• GrundySMClinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to managementCirculation2004109455155614757684
   PubMed Web of Science ®Google Scholar
• DavidsonMHCombination therapy for dyslipidemia: safety and regulatory considerationsAm J Cardiol20029010B50K60K
   PubMed Web of Science ®Google Scholar
• MartinPDAn open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteersClin Ther200325245947112749507
   PubMed Web of Science ®Google Scholar
• BergmanAJSimvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humansJ Clin Pharmacol20044491054106215317833
   PubMed Web of Science ®Google Scholar
• BackmanJTRifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolitesClin Pharmacol Ther200578215416716084850
   PubMed Web of Science ®Google Scholar
• SchneckDWThe effect of gemfibrozil on the pharmacokinetics of rosuvastatinClin Pharmacol Ther200475545546315116058
   PubMed Web of Science ®Google Scholar
• DavidsonMHSafety considerations with fibrate therapyAm J Cardiol2007996A3C18C
   PubMed Web of Science ®Google Scholar
• GrundySMImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation2004110222723915249516
   PubMed Web of Science ®Google Scholar
• CannonCPCombination therapy in the management of mixed dyslipidaemiaJ Intern Med2008263435336518324928
   PubMed Web of Science ®Google Scholar
• DevinePJDesign and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)Cardiovasc Drugs Ther200721322122517404825
   PubMed Web of Science ®Google Scholar
• BrousseauMEEffects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterolN Engl J Med2004350151505151515071125
   PubMed Web of Science ®Google Scholar
• NissenSEEffect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trialJAMA2003290172292230014600188
   PubMed Web of Science ®Google Scholar